• Company Type For Profit
  • Contact Email info@spirogen.com
  • Phone Number 44 (0) 20 7278 0555

Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. Spirogen's principal technology involves modification of members of a group of naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs). The company was founded in

2000, has 18 employees and is private equity funded.

Lists Featuring This Company

Europe, Middle East, and Africa (EMEA) Health Care Acquired Companies
2,989 Number of Organizations â€¢ $21.7B Total Funding Amount â€¢ 2,129 Number of Investors
Biotechnology Acquired Companies
3,479 Number of Organizations â€¢ $132.6B Total Funding Amount â€¢ 6,544 Number of Investors
Biotechnology Acquired Companies With More Than 100 Employees
863 Number of Organizations â€¢ $88.6B Total Funding Amount â€¢ 2,048 Number of Investors
United Kingdom Health Care Companies (Top 10K)
9,816 Number of Organizations â€¢ $43.8B Total Funding Amount â€¢ 5,705 Number of Investors
Spirogen was acquired by MedImmune for $440M on Oct 15, 2013. This deal was done in Cash.

Frequently Asked Questions

Where is Spirogen's headquarters? Spirogen is located in London, England, United Kingdom.Who invested in Spirogen? Spirogen has 2 investors including Auven Therapeutics and Cambridge Research & Innovation Ltd..How much funding has Spirogen raised to date? Spirogen has raised .When was the last funding round for Spirogen? Spirogen closed its last funding round on Oct 22, 2009 from a Private Equity round.Who are Spirogen's competitors? Alternatives and possible competitors to Spirogen may include GalapagosCellServe GmbH, and Synthena.